2-chloro-8-methoxy-4-(N-methylphenylamino)quinazoline | 124309-78-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-chloro-8-methoxy-4-(N-methylphenylamino)quinazoline
• 英文别名: 2-chloro-8-methoxy-N-methyl-N-phenylquinazolin-4-amine
• CAS: 124309-78-0
• 化学式: C₁₆H₁₄ClN₃O
• 分子量: 299.76
• InChiKey: SWDZIUAYAYUPPM-UHFFFAOYSA-N

物化性质

• 沸点：
  432.2±38.0 °C(Predicted)
• 密度：
  1.300±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-chloro-8-methoxy-4-(N-methylphenylamino)quinazoline 在 hydrazine hydrate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 2-hydrazinyl-8-methoxy-N-methyl-N-phenylquinazolin-4-amine
  参考文献：
  名称：

  [EN] DIACYLGLYCEROL KINASE MODULATING COMPOUNDS
  [FR] COMPOSÉS MODULANT LA DIACYLGLYCÉROL KINASE

  摘要：

  本公开提供了调节二酰基甘油激酶的化合物以及用于治疗癌症（包括实体瘤）和病毒感染（如HIV或乙型肝炎病毒感染）的药物组合物。这些化合物可以单独使用或与其他药物联合使用。

  公开号：

  WO2021130638A1
• 作为产物：
  描述：

  8-甲氧基喹唑啉-2,4(1h,3h)-二酮 在 sodium acetate 、 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 101.0h， 生成 2-chloro-8-methoxy-4-(N-methylphenylamino)quinazoline
  参考文献：
  名称：

  Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 5. Substituted 2,4-Diaminoquinazolines and Thienopyrimidines

  摘要：

  Quinazolines bearing a secondary 4-(arylamino) substituent demonstrate an SAR for inhibition of the gastric (H+/K+)-ATPase different from the previously described 3-acylquinolines, suggesting that, although these compounds are also K+-competitive, they probably bind to the enzyme in a different orientation. Compounds bearing a tertiary 4-(arylamino) substituent, however, in particular 4-(N-methylarylamino), appear to possess an SAR quite similar to the 3-acylquinolines. We show that this arises from the effect of the N-methylation, which is to orientate the 4-(arylamino) substituent syn to C-5, analogous to the 3-acylquinolines. Compounds possessing both a 4-(N-methylarylamino) substituent and a 2-(arylamino) substituent proved to be very potent, K+-competitive inhibitors of K+-stimulated ATPase activity with K-i values down to 12 nM. Some compounds also proved to be effective inhibitors of stimulated acid secretion in both the rat and dog when dosed intravenously. However, although a number of these demonstrated activity after oral administration in the dog, the level and variability precluded further evaluation.

  DOI：

  10.1021/jm00014a027

文献信息

• COMPOUNDS AND THERAPEUTICAL USE THEREOF
  申请人：Cai Xiong Sui

  公开号：US20070244113A1

  公开（公告）日：2007-10-18

  Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳氨基喹唑啉及其类似物，可有效激活半胱氨酸蛋白酶并诱导细胞凋亡。本发明的化合物在治疗各种临床情况中具有用途，其中异常细胞的不受控制的生长和扩散。
• Compounds and therapeutical use thereof
  申请人：Cai Xiong Sui

  公开号：US20050137213A1

  公开（公告）日：2005-06-23

  Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳基氨基喹唑啉及其类似物，它们有效地激活半胱氨酸蛋白酶并诱导细胞凋亡。本发明的化合物在治疗各种临床病症中具有用途，其中发生异常细胞的不受控制的生长和扩散。
• COMPOUNDS AND THERAPEUTICAL USES THEREOF
  申请人：Myrexis, Inc.

  公开号：US20130029942A1

  公开（公告）日：2013-01-31

  Disclosed are 4-arylamino-quinazolines and analogs thereof that are effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明揭示了4-芳基氨基喹唑啉及其类似物，它们有效地激活半胱氨酸蛋白酶并诱导细胞凋亡。该发明的化合物在治疗各种临床病症中具有用途，其中包括发生异常细胞无控制生长和扩散的情况。
• Erythromycin derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0321185A2

  公开（公告）日：1989-06-21

  9-N,11-O-methylene derivatives of erythromycin-9-imine (wherein the methylene group is optionally substituted) of the general formula IA or IB: or a pharmaceutically acceptable ester or acid addition salt thereof, wherein R¹ denotes hydrogen, an unsubstituted or substituted hydrocarbon group, a heterocyclyl group, or an acyl group; R³ denotes hydrogen or hydroxy; R⁶ denotes hydrogen or methyl; one of R⁷ and R⁸ denotes hydrogen, hydroxy, alkoxy,alkanoyloxy, amino, substituted amino, or a group of the formula R⁹-SO₂-O-, and the other of R⁷ and R⁸ denotes hydrogen, or R⁷ and R⁸ together denote an oxo group, an oxime group, or a substituted oxime group; and R⁹ denotes an organic group, possess improved acid stability, compared with erythromycin A, whilst retaining good antibacterial activity.

  通式 IA 或 IB 的红霉素-9-亚胺的 9-N,11-O-亚甲基衍生物（其中亚甲基任选被取代）： 或其药学上可接受的酯或酸加成盐、 其中 R¹ 表示氢、未取代或取代的烃基、杂环基或酰基； R³ 表示氢或羟基； R⁶ 表示氢或甲基； R⁷ 和 R⁸ 中的一个表示氢、羟基、烷氧基、烷酰氧基、氨基、取代氨基或式 R⁹-SO₂-O- 的基团，而 R⁷ 和 R⁸ 中的另一个表示氢，或 R⁷ 和 R⁸ 共同表示羰基、肟基或取代的肟基；以及 R⁹ 表示有机基团、 与红霉素 A 相比，具有更好的酸稳定性，同时保持良好的抗菌活性。
• Quinazoline derivatives
  申请人：SmithKline Beecham Intercredit B.V.

  公开号：EP0322133B1

  公开（公告）日：1991-05-22